[Unaudited Interim Condensed Consolidated Financial Statements](index=2&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) [Unaudited Interim Condensed Consolidated Statements of Loss](index=3&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Loss) Revenue grew **32.6%** to **$45.3 million**, with net loss decreasing **25.3%** to **$54.9 million** Consolidated Statement of Loss Highlights (in USD thousands) | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | YoY Change | | :--- | :--- | :--- | :--- | | **Revenue** | $45,323 | $34,176 | +32.6% | | **Gross Profit** | $31,014 | $21,624 | +43.4% | | **Operating Loss** | $(55,879) | $(72,739) | -23.2% | | **Loss for the period** | $(54,920) | $(73,478) | -25.3% | | **Basic and diluted loss per share** | $(0.85) | $(1.15) | -26.1% | [Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss](index=4&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Loss) Total comprehensive loss improved to **$52.9 million**, driven by reduced net loss and positive currency translation Consolidated Statement of Comprehensive Loss (in USD thousands) | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Loss for the period | $(54,920) | $(73,478) | | Currency translation differences | $2,269 | $(10,249) | | **Total comprehensive loss for the period** | **$(52,934)** | **$(81,274)** | [Unaudited Interim Condensed Consolidated Balance Sheets](index=5&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$205.9 million** due to reduced cash, with liabilities rising and equity falling to **$158.4 million** Key Balance Sheet Items (in USD thousands) | Asset/Liability/Equity | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $132,767 | $161,305 | | Total assets | $205,852 | $243,838 | | Total liabilities | $47,413 | $43,708 | | Total equity | $158,439 | $200,130 | [Unaudited Interim Condensed Consolidated Statements of Changes in Equity](index=6&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Equity) Total equity decreased from **$200.1 million** to **$158.4 million**, primarily due to a **$54.9 million** net loss Equity Reconciliation for Nine Months Ended Sep 30, 2023 (in USD thousands) | Description | Amount | | :--- | :--- | | Equity as of January 1, 2023 | $200,130 | | Loss for the period | $(54,920) | | Other comprehensive income | $1,986 | | Share-based compensation | $11,036 | | Other transactions with owners | $207 | | **Equity as of September 30, 2023** | **$158,439** | [Unaudited Interim Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$37.3 million**, with cash decreasing to **$132.8 million** Net Cash Flow Summary (in USD thousands) | Cash Flow Activity | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Net cash flows used in operating activities | $(37,283) | $(59,764) | | Net cash flow provided from investing activities | $10,569 | $29,835 | | Net cash flow used in financing activities | $(2,311) | $(988) | | **Cash and cash equivalents at end of the period** | **$132,767** | **$157,827** | [Notes to the Unaudited Interim Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) Detailed disclosures cover company background, accounting policies, revenue, balance sheet, and income statement items [Note 1: Company Information](index=9&type=section&id=1.%20Company%20information) SOPHiA GENETICS SA, a Swiss cloud-native software company, reduced D&O insurance cash from **$30 million** to **$15 million** - The company is a cloud-native software company in the healthcare space, commercializing its SOPHiA DDM™ platform for analyzing complex multimodal datasets[17](index=17&type=chunk) - In June **2023**, the company reduced the designated cash set aside for its Directors and Officers Insurance Policy from **$30 million** to **$15 million**[24](index=24&type=chunk) - As of September **30**, **2023**, the company held **11,766,158** treasury shares, a significant increase from **2,257,163** held a year prior, primarily for administering equity incentive programs[33](index=33&type=chunk) [Note 2: Fair Value](index=11&type=section&id=2.%20Fair%20Value) Financial assets and liabilities' carrying amounts approximate fair values as of September **30**, **2023**, with no significant changes - The carrying amount of financial assets and liabilities, including cash, accounts receivable, and accounts payable, is a reasonable approximation of their fair value as of September **30**, **2023**[35](index=35&type=chunk) [Note 3: Financial Risk Management](index=12&type=section&id=3.%20Financial%20Risk%20Management) The company faces credit, liquidity, and market risks, with no significant changes in risk management since year-end **2022** - The company is exposed to credit, funding, liquidity, and market risks, with no significant changes in its risk management approach since December **31**, **2022**[36](index=36&type=chunk) [Note 4: Segment Reporting](index=12&type=section&id=4.%20Segment%20Reporting) The company operates as a single segment, with the CEO reviewing financial information on a consolidated basis - The company operates in a single operating segment, and its performance is assessed as a whole by the senior management team led by the CEO[37](index=37&type=chunk) [Note 5: Revenue](index=12&type=section&id=5.%20Revenue) Revenue primarily from SOPHiA DDM™ Platform, with EMEA contributing **71%** and NORAM **16%**, both showing strong growth Revenue by Geographic Region (in USD thousands) | Region | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | YoY Growth | | :--- | :--- | :--- | :--- | | EMEA | $32,378 | $25,288 | +28.0% | | NORAM | $7,268 | $4,656 | +56.1% | | LATAM | $3,062 | $2,189 | +39.9% | | APAC | $2,615 | $2,043 | +28.0% | | **Total** | **$45,323** | **$34,176** | **+32.6%** | Revenue by Stream (in USD thousands) | Revenue Stream | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | SOPHiA DDM Platform | $44,331 | $32,884 | | Workflow equipment and services | $992 | $1,292 | [Note 6: Accounts Receivable](index=13&type=section&id=6.%20Accounts%20receivable) Net accounts receivable increased to **$9.8 million** from **$6.6 million**, driven by a rise in accrued contract revenue Accounts Receivable Breakdown (in USD thousands) | Component | September 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Accounts receivable | $4,631 | $6,060 | | Accrued contract revenue | $6,064 | $1,499 | | Allowance for expected credit losses | $(1,056) | $(1,095) | | **Net accounts receivable** | **$9,781** | **$6,649** | [Note 7: Loss Per Share](index=13&type=section&id=7.%20Loss%20per%20share) Loss per share improved to **$0.85** from **$1.15** for the nine months ended September **30**, **2023**, on **64.6 million** shares Loss Per Share Calculation | Metric | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Net loss attributed to shareholders (USD thousands) | $(54,920) | $(73,478) | | Weighted average number of shares in issue | 64,607,758 | 64,058,859 | | **Basic and diluted loss per share** | **$(0.85)** | **$(1.15)** | [Note 8: Leases](index=14&type=section&id=8.%20Leases) In June **2023**, a **108**-month lease for new R&D office space in France recorded a **$2.3 million** right-of-use asset and liability - On June **1**, **2023**, the company entered into a **108**-month lease for office space in Bidart, France, to support R&D expansion, recording a right-of-use asset and lease liability of **$2.3 million**[43](index=43&type=chunk) [Note 9: Borrowings](index=14&type=section&id=9.%20Borrowings) A revolving credit facility of up to **CHF 5.0 million** with Credit Suisse had no outstanding borrowings as of September **30**, **2023** - The company has a credit facility of up to **CHF 5.0 million** with Credit Suisse, with no borrowings outstanding as of September **30**, **2023**[44](index=44&type=chunk) [Note 10: Share-based Compensation](index=14&type=section&id=10.%20Share-based%20compensation) Share-based compensation expense totaled **$11.04 million**, consistent with prior year, largely from general and administrative functions Share-based Compensation Expense (in USD thousands) | Department | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Research and development | $2,489 | $1,732 | | Sales and marketing | $794 | $1,175 | | General and administrative | $7,753 | $8,110 | | **Total** | **$11,036** | **$11,017** | [Note 11: Related Party Transactions](index=14&type=section&id=11.%20Related%20party%20transactions) Key management compensation increased to **$11.0 million** from **$9.1 million**, driven by higher salaries and share-based compensation Key Management Compensation (in USD thousands) | Compensation Type | Nine months ended Sep 30, 2023 | Nine months ended Sep 30, 2022 | | :--- | :--- | :--- | | Salaries and other short-term benefits | $2,814 | $1,613 | | Share-based compensation expense | $7,713 | $7,061 | | **Total** | **$10,994** | **$9,109** | [Note 12: Events After the Reporting Date](index=15&type=section&id=12.%20Events%20after%20the%20reporting%20date) No material subsequent events requiring recognition or disclosure were identified after the reporting date through November **7**, **2023** - There were no material events after the reporting date that required recognition or disclosure in the financial statements[49](index=49&type=chunk)

SOPHiA GENETICS SA (NASDAQ:SOPH) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Katherine Bailon - Head, Investor Relations Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - Chief Financial Officer and COO Conference Call Participants Edmund Tu - Morgan Stanley Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Vidyun Bais - BTIG Operator Hello, ladies and gentlemen. And thank you for joining SOPHiA GENETICS Second Quarter 2020 Earnings Call. Our host for today is Katherin ...

Table of Contents | | Unaudited Interim Condensed Consolidated Financial Statements | F-2 | | --- | --- | --- | | – | Unaudited Interim Condensed Consolidated Statements of Loss | F-3 | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss | F-4 | | – | Unaudited Interim Condensed Consolidated Balance Sheets | F-5 | | – | Unaudited Interim Condensed Consolidated Statements of Changes in Equity | F-6 | | – | Unaudited Interim Condensed Consolidated Statements of Cash Flows | F-8 | | ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President of Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer Ross Muken - Chief Financial Officer and Chief Operating Officer Conference Call Participants Tejas Savant - Morgan Stanley Marta Nazarovets - JPMorgan Chase & Co. Kyle Boucher - TD Cowen Operator Good morning, and welcome to the SOPHiA GENETICS' First Quarter 2023 Earnings Conference Call ...

Revenue and Profitability - Revenue for Q1 2023 was $13,966 thousand, a 28.9% increase from $10,861 thousand in Q1 2022[5] - Gross profit for the period was $9,694 thousand, compared to $6,710 thousand in the same period last year, reflecting a 44.5% increase[5] - Revenue from the SOPHiA DDM Platform was $13.749 million, up from $10.431 million, indicating a growth of 31.5% year-over-year[36] - Total revenue for the three months ended March 31, 2023, was $13.966 million, representing a 28.9% increase from $10.861 million in the same period of 2022[35] Loss and Financial Performance - Operating loss decreased to $19,287 thousand in Q1 2023 from $25,021 thousand in Q1 2022, representing a 22.0% improvement[5] - Loss for the period was $19,700 thousand, down from $25,487 thousand in Q1 2022, indicating a 22.8% reduction[7] - The net loss attributed to shareholders for the three months ended March 31, 2023, was $19.700 million, an improvement from a net loss of $25.487 million in the same period of 2022[41] - Total comprehensive loss for Q1 2023 was $17,799 thousand, compared to $27,020 thousand in Q1 2022, a decrease of 34.2%[7] Cash Flow and Assets - Cash and cash equivalents at the end of Q1 2023 were $160,762 thousand, slightly down from $161,305 thousand at the end of 2022[10] - Total assets decreased to $232,058 thousand as of March 31, 2023, from $243,838 thousand at the end of 2022[10] - Accounts receivable increased to $7.696 million as of March 31, 2023, compared to $6.060 million as of December 31, 2022, reflecting a 26.9% rise[40] - The Company had no borrowings outstanding under its credit facility as of March 31, 2023[43] Shareholder Information - The company reported a basic and diluted loss per share of $0.31 for Q1 2023, an improvement from $0.40 in Q1 2022[5] - The weighted average number of shares in issue increased to 64,242,871 as of March 31, 2023, compared to 63,891,630 in the prior year[41] - The Company held 2,072,700 treasury shares as of March 31, 2023, down from 2,483,000 shares held as of March 31, 2022[30] Compensation and Expenses - Share-based compensation expense totaled $2.430 million for the three months ended March 31, 2023, compared to $3.471 million in the same period of 2022, indicating a decrease of 30%[44] - Total compensation for key management and non-executive directors decreased to $2,439,000 in Q1 2023 from $2,520,000 in Q1 2022, a decline of approximately 3.2%[47] - Share-based compensation expense reduced to $1,720,000 in Q1 2023 from $1,900,000 in Q1 2022, representing a decrease of about 9.5%[47] - Salaries and other short-term employee benefits slightly decreased to $551,000 in Q1 2023 compared to $553,000 in Q1 2022, a decline of approximately 0.4%[47] - Pension costs increased to $52,000 in Q1 2023 from $50,000 in Q1 2022, reflecting a growth of 4%[47] - Other compensation rose significantly to $116,000 in Q1 2023 from $17,000 in Q1 2022, marking an increase of approximately 582.4%[47] Other Information - The Company operates in a single operating segment, with financial performance assessed as such by senior management[34] - There were no material subsequent events reported after the reporting date[48]

SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2022 Results Earnings Conference Call March 7, 2023 8:00 AM ET Company Participants Katherine Bailon - Vice President, Investor Relations Jurgi Camblong - Founder and Chief Executive Officer Ross Muken - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Richard Hilliker, Jr. - Credit Suisse Mark Massaro - BTIG Marta Nazarovets - J.P. Morgan Operator Good morning and welcome to SOPHiA GENETICS' Fourth Quarter Fisca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (For the fiscal year ended December 31, 2022) Rue du Centre 172 CH-1025 Saint-Sulpice Switzerland +41 21 694 10 60 (Address of principal executive offices) Ross Muken OR o TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Consolidated Financial Statements of SOPHiA GENETICS SA for the year ended December 31, 2022 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the consolidated financial statements 2022 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the consolidated financial statements Opinion We have audited the consolidated financial statements of SOPHiA GENETICS SA and its subsidiaries (the Group), which comprise ...

Start Time: 08:30 January 1, 0000 9:27 AM ET SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Jurgi Camblong - Founder and CEO Ross Muken - CFO Philippe Menu - Chief Medical Officer Jennifer Pottage - Head, IR Conference Call Participants Julia Qin - JPMorgan Kyle Boucher - Cowen Vidyun Bais - BTIG Operator Good morning, everyone, and welcome to the SOPHiA GENETICS Third Quarter 2022 Earnings Conference Call. All participants will be in a ...

Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents | | Unaudited Interim Condensed Consolidated Financial Statements | F-2 | | --- | --- | --- | | – | Unaudited Interim Condensed Consolidated Statements of Loss | F-3 | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss | F-4 | | – | Unaudited Interim Condensed Consolidated Balance Sheets | F-5 | | – | Unaudited Interim Condensed Consolidated Statements of Changes in Equity | F-6 | | – | Unaudited Interim C ...